Literature DB >> 25145434

Immunotherapy in pediatric malignancies: current status and future perspectives.

Christian M Capitini1, Mario Otto, Kenneth B DeSantes, Paul M Sondel.   

Abstract

Novel immune-based therapies are becoming available as additions to, and in some cases as alternatives to, the traditional treatment modalities such as chemotherapy, surgery and radiation that have improved outcomes for childhood cancer for decades. In this article, we will discuss what immunotherapies are being tested in the clinic, barriers to widespread application, and the future of immuno-oncology for childhood cancer. While in many cases, these therapies have shown dramatic responses in the setting of refractory or relapsed cancer, much remains to be learned about how to integrate these therapies into existing upfront regimens. The progress and challenges of developing immunotherapies for childhood cancer in a timely and cost-effective fashion will be discussed.

Entities:  

Keywords:  Toll-like receptors; childhood cancer; chimeric antigen receptors; cytokines; immunotherapy; monoclonal antibodies; natural killer cells; vaccines

Mesh:

Substances:

Year:  2014        PMID: 25145434      PMCID: PMC4793725          DOI: 10.2217/fon.14.62

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  161 in total

Review 1.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

2.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

Authors:  Alberto S Pappo; Shreyaskumar R Patel; John Crowley; Denise K Reinke; Klaus-Peter Kuenkele; Sant P Chawla; Guy C Toner; Robert G Maki; Paul A Meyers; Rashmi Chugh; Kristen N Ganjoo; Scott M Schuetze; Heribert Juergens; Michael G Leahy; Birgit Geoerger; Robert S Benjamin; Lee J Helman; Laurence H Baker
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

3.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal:  Lancet Oncol       Date:  2012-02-21       Impact factor: 41.316

4.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

5.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

6.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

7.  Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Authors:  Nai-Kong V Cheung; Irene Y Cheung; Brian H Kushner; Irina Ostrovnaya; Elizabeth Chamberlain; Kim Kramer; Shakeel Modak
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Authors:  James G Taylor; Adam T Cheuk; Patricia S Tsang; Joon-Yong Chung; Young K Song; Krupa Desai; Yanlin Yu; Qing-Rong Chen; Kushal Shah; Victoria Youngblood; Jun Fang; Su Young Kim; Choh Yeung; Lee J Helman; Arnulfo Mendoza; Vu Ngo; Louis M Staudt; Jun S Wei; Chand Khanna; Daniel Catchpoole; Stephen J Qualman; Stephen M Hewitt; Glenn Merlino; Stephen J Chanock; Javed Khan
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

10.  IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.

Authors:  Claudia Brehm; Sabine Huenecke; Andrea Quaiser; Ruth Esser; Melanie Bremm; Stephan Kloess; Jan Soerensen; Hermann Kreyenberg; Christian Seidl; Petra S A Becker; Heiko Mühl; Thomas Klingebiel; Peter Bader; Jakob R Passweg; Dirk Schwabe; Ulrike Koehl
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

View more
  7 in total

Review 1.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 2.  NK cell-based immunotherapies in Pediatric Oncology.

Authors:  Kimberly A McDowell; Jacquelyn A Hank; Kenneth B DeSantes; Christian M Capitini; Mario Otto; Paul M Sondel
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

3.  Immunomodulatory Response Triggered by the Alkaloids, 3-Amino-7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (ABQ-48) and 3-Nitro-7-Benzylbenzimidazo [3,2-a] Quinolinium Chloride (NBQ-48).

Authors:  Miguel Otero; Beatriz Zayas; Eric Miranda; Christian Velez; Wigberto J Hernandez; Luis A Rivera; Osvaldo Cox
Journal:  J Cancer Res Ther Oncol       Date:  2015-05-04

4.  Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.

Authors:  Chiara Camisaschi; Salvatore Lorenzo Renne; Valeria Beretta; Francesca Rini; Rosalin Dolores Spagnuolo; Alessandra Tuccitto; Marta Giorgia Podda; Giorgio Parmiani; Licia Rivoltini; Paola Collini; Chiara Castelli; Roberto Luksch
Journal:  BMC Cancer       Date:  2018-10-16       Impact factor: 4.430

Review 5.  Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Mary Frances Wedekind; Nicholas L Denton; Chun-Yu Chen; Timothy P Cripe
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

6.  Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology Group

Authors:  Janice S Withycombe; Aimee Carlson; Carly Coleman; Sharon L Leslie; Micah Skeens; Hanna Tseitlin; Elizabeth A Duffy
Journal:  J Pediatr Oncol Nurs       Date:  2020-10-28       Impact factor: 1.636

Review 7.  Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.

Authors:  Michael A Huang; Deepa K Krishnadas; Kenneth G Lucas
Journal:  J Immunol Res       Date:  2015-10-26       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.